Recombinant human growth hormone activates neuroprotective growth factors in hypoxic brain injury in neonatal mice.

R. Trollmann,H. Dörr,Klara Terörde,Susan Jung
DOI: https://doi.org/10.1210/endocr/bqab008
IF: 5.051
2021-01-13
Endocrinology
Abstract:Perinatal hypoxia severely disrupts cerebral metabolic and maturational programs beyond apoptotic cell death. Anti-apoptotic treatments such as erythropoietin are suggested to improve outcomes in hypoxic brain injury, however, the results are controversial. We analyzed neuroprotective effects of growth hormone (rhGH) on regenerative mechanisms in the hypoxic developing mouse brain in comparison to controls. Using an established model of neonatal acute hypoxia (8% O₂, 6 h), P7 mice were treated i.p. with rhGH (4,000 µg/kg) 0/12/24 h after hypoxic exposure. After a regeneration period of 48 h, expression of hypoxia-inducible neurotrophic factors (EPO, VEGF-A, IGF-1/-2, IGF binding proteins) and pro-inflammatory markers was analyzed. In vitro experiments were performed using primary mouse cortical neurons (E14, DIV6). RhGH increased neuronal gene expression of EPO, IGF-1, and VEGF (p < 0.05) in vitro, and diminished apoptosis of hypoxic neurons in a dose-dependent manner. In the developing brain, rhGH treatment led to a notable reduction of apoptosis in the subventricular zone and hippocampus (p < 0.05), abolished hypoxia-induced downregulation of IGF-1/IGF-2 expression (p < 0.05), and led to a significant accumulation of endogenous EPO protein and anti-inflammatory effects through modulation of IL-1ß and TNF-α signaling as well as up-regulation of cerebral pERK1/2 levels. Indicating stabilizing effects on BBB, rhGH significantly modified cerebrovascular occludin expression. Thus, we conclude that rhGH mediates neuroprotective effects by the activation of endogenous neurotrophic growth factors and BBB stabilization. In addition, the modification of ERK1/2 pathways is involved in neuroprotective actions of rhGH. Present study adds further evidence that pharmacologic activation of neurotrophic growth factors may be a promising target for neonatal neuroprotection.
Medicine
What problem does this paper attempt to address?